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1. ABSTRACT  
 
Multi-drug resistant and more virulent strains of bacteria are a serious concern for 
microbiologists and medical practitioners. Many common disease causing organisms are 
becoming resistant to multiple classes of antibiotics. Recent research has given us a greater 
understanding of the issues with bacterial adaptations to drugs, multi-drug resistance, biofilms, 
and infection site microenvironments.  The new understanding of bacterial resistance has led to 
experimentation for new and potentially more efficacious drug delivery systems.  One such 
delivery system is nanoparticles. Nanoparticles offer a way to target antibiotic treatment to the 
site of infection. This feature provides treatment with two major benefits: increased antibiotic 
efficacy, and reduced antibiotic toxicity.  
  
2. INTRODUCTION  
 
The prospect that disease causing bacteria are rapidly developing resistance to our current 
repertoire of antibiotics should raise the alarm of every health care provider and citizen in the 
country. Paradoxically, the widespread use, and misuse, of antibiotics in healthcare and 
agriculture have resulted in the rapid rise of drug resistant strains of bacteria. Unfortunately, the 
consequence of nearly a century of antibiotic use is now culminating in the emergence of 
multidrug resistant strains of bacteria. Government and non-government organizations such as 
the U. S. Centers for Disease Control and Prevention (CDC), the World Health Organization 
(WHO), and the Pew Charitable Trust have become advocates to raise public awareness of the 
urgency to discover new drug delivery methods, such as nanoparticles, new antibiotics, and for 
more prudent stewardship of existing antibiotics.   
 
2.1 Scope of the Issue and Current Trends 
 
The CDC reports that the United States experiences more than two million antibiotic-resistant 
bacterial infections a year, 23,000 people die as a direct result of those infections, and many 
more people die from health conditions that were complicated by an antibiotic-resistant 
infection.1 Almost 250,000 people require hospital care each year for Clostridium difficile (C. 
difficile), an opportunistic nosocomial infection and an urgent drug resistant species. In most of 
these infections, the use of antibiotics was a major contributing factor leading to the illness. Of 
the people infected by C. difficile, at least 14,000 die in the United States. The CDC report 
estimates that 50% of prescribed antibiotics are unnecessary or not optimally effective as 
prescribed.1  
  
The agricultural industry and veterinary medicine are also significant users of antibiotics.2 
Estimates ranging from 40 to 80 percent of all antibiotics sold are for use in agriculture, and 
96% of those sales are over the counter. The FDA now tracks medically important antibiotic use 
in food animal production. Historically, antibiotics have been routinely added to food and water 
to prevent, control, and treat disease, and to promote growth. Beginning in 2017, this practice is 
now allowed only under the authorization of a veterinarian.3 
 
The 2013 CDC report was intended to raise awareness on the most significant disease causing 
bacteria. They highlight 18 species of bacteria that pose a risk due to antibiotic resistance, and 
ranked these 18 species into three categories based on several criteria including rate of 
incidence, economic cost, transmissibility, available antibiotic treatment, barriers to prevention. 
This is summarized in Figure 1 (page 2).   
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Figure 1. A thorough list of the many drug resistant bacteria facing healthcare today categorized by the 
danger they present. The classifications were based of several criteria including: rate of incidence, 
economic cost, transmissibility, available antibiotic treatment, barriers to prevention.1 
 
The Pew Charitable Trusts produced a fact sheet based on recent CDC data.4 Figure 2 (page 3) 
shows the recent trends for antibiotic prescriptions in the United States. Although overall 
antibiotic use remained fairly static, the classes of antibiotics being prescribed are changing. 
Physicians prescribe more broad-spectrum antibiotics while narrow spectrum antibiotic use is 
decreasing. Broad-spectrum antibiotics target a wide array of bacterial pathogens. They include 
glycopeptides, beta-lactam beta-lactamase inhibitor combinations, carbapenems, 
fluoroquinolones, macrolides, and third- and fourth-generation cephalosporins. Narrow-
spectrum antibiotics are effective in treating a limited and targeted group of pathogens. They 
include penicillins, aminoglycosides, and first- and second-generation cephalosporins. This 
trend is concerning because broad-spectrum antibiotics show increased risk of drug-resistant 
infections.4 By affecting non-targeted commensals in the body, antibiotics increase drug 
resistance of these organisms.  Also, most of these antibiotics can be toxic with serious side 
effects.  Broad-spectrum antibiotics are not needed for bacterial infections that can be treated 
with narrow-spectrum drugs like penicillin. Antibiotic stewardship efforts are being implemented 
to guide practitioners to prudent use of appropriate antibiotics in hospital, outpatient clinics, and 
veterinary practice settings. 
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Figure 2.  Prescribing trends for antibiotics in the U.S. 2006-2012. The use of several broad-spectrum 
antibiotics has increased during this time period.4 
 
The data presented in this introduction highlight a limitation of traditional antibiotics, which are 
losing efficacy against bacteria. This report will discuss how bacterial resistance becomes a 
problem and how bacteria are able to defend themselves from antibiotics. It will discuss how 
researchers are using nanoparticles to overcome the issues of dose vs toxicity, targeting, and 
resistance mechanisms. 
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3. ANTIBIOTIC RESISTANCE 
 
The CDC defines antimicrobial resistance as the result that occurs when from microorganisms 
change in order to reduce or eliminate the effectiveness of drugs, chemicals, or other agents 
used to cure or prevent infections.1 The interesting takeaway from this definition is the co-
dependent nature of antibiotic resistance and antibiotics. Antibiotic resistance cannot propagate 
without the use of antibiotics, and antibiotic use does not occur without propagating antibiotic 
resistance. Thus, antibiotic consumption has contributed to the emergence of antibiotic 
resistance in various bacterial genera.5 In fact, some antibiotic-resistant bacterial strains are 
named for the drug which gave their rise. Well-known examples include Methicillin-Resistant 
Staphylococcus aureus (MRSA), which emerged in the 1960s, and Vancomycin-Resistant 
Enterococci (VRE) which emerged in the 1990s. Unfortunately, they remain a public health 
concern even as more antibiotic resistant organisms emerge, continuously adding to the pool of 
antibiotic resistant genes. 
 
The development of resistance is linked to how often antibiotics are used and the genetic 
variability of the bacteria. Because many antibiotics belong to the same class of medicines, 
resistance to one specific antibiotic agent can lead to resistance to the whole class. Resistance 
that develops in one organism or location can spread rapidly and unpredictably, through the 
processes of horizontal gene transfer and affect antibiotic treatment of a wide range of 
infections and diseases. Drug-resistant bacteria circulate in populations of human beings and 
animals, through food, water and the environment, and transmission is influenced by trade, 
travel, and both human and animal migration. The result is a pool of antibiotic resistance genes 
and their precursors in pathogenic and non-pathogenic bacteria, which is known as the 
resistome.6  Antibiotic resistance genes are composed of four different types: resistance genes 
found in pathogenic bacteria, resistance genes found in antibiotic producing organisms for their 
own protection, cryptic resistance genes which are phenotypically silent DNA sequences not 
typically expressed during the lifecycle of bacteria and that do not obviously confer resistance 
due to low level of expression, and precursor genes that may evolve into full resistance genes 
under the appropriate selective pressure. 
 
Bacterial antibiotic resistance is classified into three categories.7 Intrinsic resistance comprises 
the inherent properties provided by the microorganism, such as the semipermeable cell wall, 
efflux pump, and enzymes that degrade antibiotics. Acquired resistance occurs when previously 
susceptible bacteria become resistant by incorporating new genetic material through horizontal 
gene transfer or mutation. Adaptive resistance is the temporal ability to cope with antibiotics 
through rapid development of resistance. It emerges when populations of bacteria are subjected 
to gradual increases of antibiotics and quickly reverses when antibiotics are removed. Adaptive 
resistance requires epigenetic inheritance and heterogeneity in the population. It is likely a 
combination of epigenetic processes such as methylation and the variability in expression in 
methylated genes account for adaptive resistance.8 
 
3.1 How Bacteria Develop Resistance 
 
Bacteria develop resistance by genetic change through mutation, horizontal gene transfer, 
epigenetic changes, and genetic variation or heterogeneity.7 
 
Changes in the bacterial genome that occur through mutation or horizontal gene acquisition 
lead to changes in the proteins expressed by the bacteria. A challenge to pathogen survival is 
the need to overcome the defenses of the target host and antibiotics. These defenses cause 
	 5	
stress, such as oxidative stress, that damage the pathogen’s genome. Bacteria engage in 
horizontal gene transfer, which benefits the bacteria because it allows the exchange of DNA to 
repair genomic damage. Horizontal gene transfer is the acquisition of foreign DNA from 
plasmids, transposons, integrons, and naked DNA. It is one of the most important drivers of 
bacterial evolution. Plasmid-mediated resistance is the transfer of antibiotic resistance genes 
which are carried on plasmids and transferred between bacteria, even between species, via 
conjugation.  Phage mediated transduction is the transfer through viruses.  Bacterial 
transformation involves the transfer of DNA from one bacterium to another through the 
surrounding medium.  The DNA is incorporated into the bacterial chromosome by 
recombination. 
 
3.2 Antibiotic Resistance Mechanisms 
 
Antibiotic resistance is accomplished by several mechanisms that prevent access of the 
antibiotic to its target or alter the antibiotic target in order to render the antibiotic useless. These 
mechanisms include: reduced drug permeability across the bacterial cell wall, increased 
antibiotic efflux from the microbial cell, antibiotic inactivation by microbial enzymes, 
overproduction of the target enzyme, acquisition of alternative metabolic pathways to those 
inhibited by the drug, and modification of antibiotic targets. In addition, bacteria that exist as 
biofilms or intracellular pathogens benefit from an additional barrier that blocks antibiotics. 
   
3.2.1 Reduced permeability to antibiotics 
  
Many antibiotics act on an intracellular target. In order to reach these intracellular targets, 
antibiotics must pass through the cell membrane via channels or porins. There are several 
protein families that can affect the ability of antibiotics to cross the cell membrane. This form of 
antibiotic resistance is referred to as reduced permeability or decreased antibiotic penetration, 
and it results in reduced internalization of antibiotics. Clinically relevant drugs with intracellular 
targets that are affected by reduced permeability include: beta-lactams, fluoroquinolones, 
aminoglycosides, and tetracyclines.9 The major cause of reduced permeability is altering 
membrane bound porin molecules. Porin molecules permit the transport of hydrophilic 
substances across the outer membrane and the cytoplasmic membrane. They are altered in 
three ways to increase resistance: shifting the type of porins expressed, changing the level of 
porins expressed, and impairing porin function.9 
  
Outer membrane porins (Opr) are a broad family of porins found in gram-negative bacteria that 
offers a variety of substrate selectivities. An important example is OprD found in Pseudomonas 
aeruginosa and Acinetobacter baumannii. In P. aeruginosa, OprD allows uptake of basic 
molecules such as imipenem. According to a study by Yan et al, a four-nucleotide base-pair 
insertion to the oprD gene resulted in a conformational change in the OprD channel that 
reduced its permeability to carbapenem antibiotics.10 Additional outer membrane porins include 
OmpF and OmpC.  OmpF allows passage of beta-lactam antibiotics into the periplasmic space. 
When under antibiotic stress, Escherichia coli reduce the expression of OmpF. Therefore, 
reduced permeability of beta-lactams limits their effect against E. coli. In a similar way, OmpC is 
down-regulated when subjected to antibiotic stress.11 A plethora of other bacteria also have 
reduced beta-lactam permeability due to porin changes. 
  
Sugar porins are a family of transporter molecules that specialize in transporting sugars across 
the outer membrane of Gram negative bacteria, but also permit the transport of tetracyclines 
and fluoroquinolones. LamB variants in E. coli reduce permeability to these drugs as explained 
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in Lin et al.12 MltA-interacting protein (MipA) in E. coli is a transporter of aminoglycosides and 
fluoroquinolones. Often this porin is lost in resistant bacterial strains.13   
 
3.2.2 Antibiotic efflux 
  
Reduced permeability often works together with another form of resistance permitted by efflux 
pumps. Efflux proteins pump material, including antibiotics, from inside the cell to the external 
environment. The effect of antibiotic efflux is reduced concentration and efficacy of intracellular 
antibiotics. There are a variety of protein families that convey drug resistance through efflux 
pumps. 
  
Major facilitator superfamily (MFS) is a large and diverse superfamily of secondary active 
transporters. In gram-positive bacteria, this family of efflux pumps work as monomeric 
antiporters. Meanwhile, in gram-negative bacteria, they may be paired with other outer 
membrane pumps. A major group of MFS transporters are the tet family proteins which offer 
resistance to tetracycline.14  
  
Several other classes of efflux pumps include: small multidrug resistance transporters (SMR), 
ATP-binding cassette transporters (ABC), the resistance-nodulation-division proteins (RND), 
and multidrug and toxic compound extrusion transporter (MATE) as demonstrated in Figure 3 
(page 7). The SMR efflux pump family is a secondary active transporter family. Important 
examples of this family include EmrE in E. coli and Smr-2 in S. aureus and P. aeruginosa.15 
RND proteins are a broad family of proteins, which include some secondary transporters. 
Important examples include the AcrAB-TolC system in Enterbacteriaceae and the MexAB-OprM 
system in P. aeruginosa.16 Researchers at Iowa State University have recently demonstrated 
the transport dynamics of an important multidrug RND efflux pump in Campylobacter jejuni.17 
This process includes the synchronized motion of three subunits along with independent 
conformational changes for each subunit. MATE transporters utilize a cationic gradient to pump 
out constituents. They are effective at removing quinolones.18 Finally, the ABC transporters are 
a large and diverse family of primary active transporters that includes several efflux pumps, and 
provide multiple drug resistance.  
 
3.2.3 Enzymatic antibiotic inactivation  
  
Most antibiotics catalyze or block an action with high specificity for a target molecule. Alteration 
of the antibiotic through enzymatic modification is another way in which bacteria can acquire 
resistance. A well-known example of this form of resistance is β-lactamase. This enzyme offers 
resistance to β-lactam antibiotics such as penicillins and cephalosporins through breaking the 
cyclic structure of the antibiotic.19 Aminoglycosides are also commonly inactivated by chemical 
reactions like acylation and phosphorylation.19 There are several known enzymatic modifications 
bacteria have employed to gain antibiotic resistance including: glycosylation, hydrolysis, 
phosphorylation, acylation, and hydroxylation.  
 
3.2.4 Changes at the antibiotic target 
 
Antibiotic resistance through changes at the antibiotic target includes overproduction of the 
target enzyme, acquisition of alternative metabolic pathways to those inhibited by the drug, and 
modification of antibiotic target sites through enzymatic or mutational alterations. For example, 
mutations to ribosomal RNA can reduce the binding affinity for antibiotics such as tetracycline 
and aminoglycosides.20 Vester et al provides a good summary of rRNA mutations that allow 
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resistance to macrolide antibiotics.21 Mutations to penicillin-binding protein permit resistance to 
the several β-lactam antibiotics.  There are also mutations to topoisomerase that provide 
resistance to quinolones. The consequences of these mutations are demonstrated in Figure 4 
(page 8).22 Beyond simple mutations, bacteria can bypass the effects of antibiotics by producing 
functionally similar but structurally different proteins. Sulfonamide resistance, for example, 
works in this way.23  
 
 
Figure 3. The various efflux pump classes and the antibiotics they’re effective against.9 
  
 
3.2.5 Physical barriers for drug evasion 
 
Biofilms and intracellular life are two ways bacteria can evade antibiotic treatment. The bacteria 
that exist in biofilms produce an extracellular matrix that provides a barrier to antibiotic treatment 
and host immune response, thus creating a protective niche in the body. In fact, biofilms confer 
up to 1000 times more resistance to antibiotics than planktonic bacteria.24 Several clinically 
relevant biofilm-forming bacteria include: P. aeruginosa, S. aureus, and Enterococci. A common 
component of biofilms is extracellular DNA, including DNA that encodes resistance genes, 
which is shared among the bacteria existing in the biofilm. Additionally, a fraction of bacteria in 
biofilms exist as “persisters.” These bacteria are in a non-reproductive, non-growing state that 
permits insensitivity to antibiotics. When treating a biofilm with antibiotics, persisters often 
outlast the antibiotic treatment and prolong the infection when they reactivate.24 This leads to 
chronic infections resistant to treatment.  
 
The other major physical barrier some bacteria utilize to evade antibiotic treatment is 
intracellular life in host cells. The intracellular lifestyle often occurs in phagocytic cells where 
bacteria such as Listeria and Brucella have evolved ways to avoid degradation in the 
phagolysosome, and subsequently proliferate in the phagocytic cell.25 Additionally, using 
antibiotics against intracellular pathogens requires the antibiotic to accumulate in both the 
phagocytic cell and the intracellular compartment of the phagocyte at sufficiently high 
concentrations. Even then the bacteria may express resistant genes. Unfortunately, this makes 
treatment of these organisms difficult, and offers a high incidence of antibiotic treatment 
failure.26  
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Figure 4. The impact mutations of topoisomerase 2 have on the concentration of quinolones required to 
be effective (MIC). The size of the circle represents the frequency each strain was encountered in clinical 
isolates from the study in Bruchmann et al.22 
 
3.3 Limitations of Antibiotic Treatment 
 
Antibiotics attack bacteria by targeting biochemical reactions, structural features, or both. The 
effects of antibiotics are either bactericidal if they kill their target or bacteriostatic if they inhibit 
cell division. Antibiotics work best when they target features specific to bacteria, thereby limiting 
unwanted side-effects to the host. However, no drugs are perfect and most if not all antibiotics 
carry the risk for adverse effects in the body. The prevalence of adverse effects increases as 
the dose of antibiotic increases, which is sometimes necessary to defeat antibiotic-resistant 
bacteria. 
 
The limitation of antibiotics is their toxicity, lack of targeting, and ineffective treatment against 
resistant bacteria. The problem created by these three limitations lies at the heart of the 
impending threat bacteria pose to modern health, and is exactly where nanoparticles can most 
contribute.  
 
4. NANOPARTICLES 
 
Many advocates for nanoparticles, and nanotechnology in general, predict that they are on the 
precipice of mainstream medicinal use.27,28 Nanoparticles have the potential for more effective 
drug treatment through targeted drug delivery, intrinsic antimicrobial activity, and 
functionalization to overcome antibiotic resistance. 
 
4.1 General Characteristics 
 
Nanoparticles are incredibly small. The nanoscale, as demonstrated in Figure 5 (page 9), 
ranges from 1-1000 nanometers, or between the size of a typical bacterium down to the 
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diameter of a few adjacent silicon atoms.29 At this small size, interesting physical and biological 
features arise. In the context of medicine, nanoparticles are most useful at less than 100 nm, 
which allows passage through capillary fenestrations around the site of infection.28 
Nanoparticles can take various shapes like round or filamentous.30 
 
 
Figure 5. Nanoparticles of various chemical compositions fit comfortably in the nanoscale range. Several 
types of nanoparticles are highlighted in section 4.2.29 
 
4.2 Types of Nanoparticles 
 
The term nanoparticles refers to any particle in the nanoscale, but composition of those particles 
can be quite varied. To assist in categorizing nanoparticles, they have been classified into 
groups based on the chemical compositions. Several review articles summarize the 
classification of nanoparticles into the following groups: liposomes, solid-lipid nanoparticles, 
polymeric nanoparticles, polymeric micelles, dendrimers, and several types of inorganic 
nanoparticles made of gold, silver, silica, iron-oxide and others.31,28,29  
  
Liposomes are small lipid colloids that consist of a central aqueous space surrounded by a lipid 
bilayer with diameter ranging between 20-100 nanometers.28 Typically, liposomes near the 20-
nanometer range are unilamellar micelles, whereas those near the 100-nanometer range are 
bilayered vesicles.31 Liposomes are self-assembling in aqueous solution, and are often 
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prepared by sonication.29  Being phospholipids, liposomes are more biocompatible than other 
nanoparticles. However, they may leak their loaded cargo, and experience uptake and removal 
by phagocytic cells. 
  
Solid-lipid nanoparticles are another lipid-based nanoparticle composition that uses lipids that 
exist as solids around body temperature, for example acetyl palmitate or salts of myristic acid.31 
They are also relatively biocompatible, and can be tailored for controlled cargo release for 
various environments. They are also more stable that their liposomal counterparts. The 
limitation of solid-lipid nanoparticles is their tendency to form gels and low loading capacity for 
antibiotics.29  
  
Polymeric nanoparticles are matrix polymers with hydrophilic and hydrophobic regions. 
Synthetic polymeric nanoparticles are typically made of polyesters like polylactide, 
polycaprolactones, or polyacrylates.31 They are also comprised of various other organic 
compounds. At Iowa State University, polyanhydride nanoparticles are a major focus of 
research.32 Polymeric nanoparticles are also formed from natural substances like albumin, 
alginate, or chitosan. These particles are stable in the body and can be tailored to degrade and 
release their cargo in specific environments. They also are associated with reduced ability to 
adjust dosage and are difficult to handle. Antibiotics can be attached to the surface of the 
nanoparticle, or dispersed through the particle during polymerization.28  
  
Another class of polymeric nanoparticles are polymeric micelles, which are formed from block 
copolymers or polymers with two distinct blocks. One block forms the hydrophobic inner shell 
while the second block forms the hydrophilic outer shell. Drugs like antibiotics are either 
physically encapsulated or otherwise attached through covalent bonding.28 These nanoparticles 
can effectively package hydrophobic cargo and accumulate at the target with enhanced 
permeability, but they also have low drug incorporation stability which could result in loss of the 
cargo before reaching the target site.31 
  
In addition to the organic-based nanoparticles there are a variety of inorganic nanoparticles. The 
most prominent of these are gold, silver, iron-oxide, and other metal nanoparticles. Like organic 
nanoparticles, these nanoparticles can be modified to have a variety of cargo-loading, cytotoxic, 
and other characteristics. These nanoparticles can be smaller with greater loading capacity and 
higher antimicrobial activity than other nanoparticles. However, they have lower biodegradability 
and are harder to excrete from the body. Therefore, inorganic nanoparticles tend be more toxic 
than their organic counterparts.31 
  
4.3 Functionalization 
 
One of the most important features of nanoparticles is their so-called “functionalization,” in 
which they are engineered to demonstrate specific features. Nanoparticles have been 
functionalized for many of purposes including drug delivery. One form of functionalization that is 
a focus of this paper is surface functionalization. Surface functionalization involves the 
conjugation of various chemical features to the surface of the nanoparticle. In practice, this 
means chemists can attach different ligands to the nanoparticles. This is perhaps the most 
exciting feature of nanoparticles, because of its powerful effect on biodistribution. Researchers 
have attached various ligands to nanoparticles including various small molecules, dendrimers, 
polymers, antibodies and other biomolecules.33 Several of these ligands are highlighted in 
Figure 6 (page11). Attaching ligands to the surface of nanoparticles offers two benefits for drug 
delivery. The first is providing nanoparticles a way for “biosensing,” or specific recognition of the 
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target biomolecule. For treating infections, this is usually a bacterial receptor. The second 
advantage is offering nanoparticles a form of “stealth,” or preventing particle capture by the 
immune system.33 Together, these features increase delivery of antibiotics to the infection, 
reduce random dispersal of antibiotics in the body, and increase the half-life of circulating 
antibiotic loaded nanoparticle. Several examples of this process are shown later in this report. 
 
 
Figure 6. Several forms of surface functionalization. Section 5.2 highlights recent research involving these 
various ligand types.31 
 
5. NANOPARTICLES APPLICATIONS IN ANTIBACTERIAL DRUG THERAPY 
 
The progress in nanoparticle research to fight antibacterial drug resistance is summarized in 
several recent comprehensive review articles, including those by.31,34,35,36 These reviews 
indicate the potential benefits of nanoparticle treatment including their controlled distribution of 
payload drugs, targeted delivery of antibiotics to the site of infection, exploitation of 
the microenvironment for controlled antibiotic release, and their potential against intracellular 
pathogens and biofilms. 
 
5.1 Drug Distribution 
  
The physical properties of nanoparticles such as size, shape, hydrophilicity, and zeta-potential 
affect their distribution in the body. These features are an advantage over traditional delivery 
methods. For example, orally administered antibiotics rely on high concentration with random 
distribution throughout the body to reach the intended target tissues in adequate concentration. 
This form of uncontrolled delivery means much of the administered drug accumulates in 
uninfected host tissues. The previously mentioned physical properties of nanoparticles can be 
tailored to encourage delivery of nanoparticles to the site of infection, while avoiding 
accumulation in non-infected tissue. 
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Zaidi et al notes the importance of particle size in determining the distribution of nanoparticles in 
the body.31 Small nanoparticles are distributed throughout the body more rapidly and evade 
macrophages more efficiently than large particles. Small nanoparticles are also more efficiently 
loaded with antibiotic than large nanoparticles. These phenomena allow smaller nanoparticles to 
deliver more antibiotic more quickly to the site of infection than larger nanoparticles. However, 
nanoparticles smaller than five nanometers can be rapidly cleared by the kidneys, and thus lose 
distribution to the body.31 Also, smaller nanoparticles lose some selectivity in drug distribution as 
they can accumulate in more areas of the body beyond just the site of infection.  
  
The shape of the nanoparticle is an important variable for the rate of clearance and 
phagocytosis. Studies have shown that particles of the same size, but different shapes have 
different distribution. Filamentous particles exist in circulation 10 times longer than spherical 
nanoparticles with similar composition highlighting the major role shape plays in the circulating 
half-life of a particle.37 Additionally, particle shape plays a major role in phagocytosis by 
influencing the actin structures needed for internalization. Shape seems to play at least as 
important if not more important role in phagocytosis than size.30  
 
Two other important physical properties include surface features such as hydrophilicity, and 
zeta-potential. These physical properties affect the way nanoparticles interact with cell 
membranes, proteins, and each other with consequences that include protein adsorption, 
endocytosis, and distribution in the body or cell. For example, increasing the hydrophilicity of a 
nanoparticle reduces its opsonization by antibodies, which prevents clearance by cells in the 
liver or spleen. On the other hand, increasing hydrophobicity promotes uptake by cells and 
therefore less distribution in the body.31,38 Zeta-potential is an electrokinetic property that 
measures the resistance of colloidal particles to coagulate. Having similarly charged 
nanoparticles can increase their zeta-potential, thus reducing their coagulation to each other 
while promoting their attraction to cell membranes of opposite charge.  Zeta-potential above +40 
mV are known to alter bacterial cell membrane permeability by acting as detergents, causing 
osmotic damage and cell death.34 
   
5.2 Drug Targeting 
  
Perhaps the most exciting and important prospect of nanoparticles is their potential for targeted 
drug delivery. Selectively targeting antibiotics to the site of infection through delivery by 
nanoparticles offers a way to avoid drug delivery to unintended locations and the toxicity 
associated with it. At the same time, targeted delivery can potentially increase the efficacy of 
antibiotics, and reduce the emergence of drug resistance.  Nanoparticles accomplish targeted 
drug delivery through passive or active mechanisms.  
  
Passive mechanisms rely on changes that occur around the site of infection, such as increased 
vascular permeability, as a route for targeting.35 Bacterial components, like lipopolysaccharides 
or lipoteichoic acid, accumulate at the site of infection and trigger inflammation. This 
inflammatory response promotes increased vascular permeability by allowing gap widening, and 
barrier dysfunction as the vasculature dilates. These features, along with reduced lymphatic 
drainage, promote the enhanced permeation and retention effect as shown in Figure 7 (page 
13).39 Nanoparticles can take advantage from this naturally occurring process for their own 
accumulation at the site of infection through manipulation of several features like size or shape 
that increase permeability in the locally dilated vasculature.31,40 Once reaching the site of 
infection the nanoparticles degrade and release their antibiotic payload. Laverman et al provide 
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evidence for this passive mechanism.41 They showed that liposomes, including PEGylated 
liposomes, accumulate in soft tissue infected by Staphylococcus aureus. Scintigraphy from their 
study is shown as Figure 8 (page 14). 
 
Active targeting expands on the principles of passive targeting for further control of drug 
delivery. Active targeting utilizes specific features of the bacterial cell surface, such as charge or 
ligand receptors, as foci for accumulation. Many bacteria maintain a negatively charged 
surface.35 Nanoparticles with a positive charge use electrostatic potential in order to accumulate 
on the bacteria.42 Positively charged peptide nanoparticles may be used for direct toxicity to 
infections while reducing toxicity to other tissues.43 In one particularly interesting example, 
zwitterionic gold nanoparticles react to the pH microenvironment around an infection and switch 
to a positive charge. While positively charged, the nanoparticles aggregate to the bacterial cell 
wall.44 Active targeting is also accomplished by conjugating nanoparticles with ligands that 
directly bind with pathogens.35 For example, vancomycin is a ligand that strongly attaches to the 
surface of gram-positive bacteria by binding to alanine moieties in the cell wall. It also has some 
affinity for the receptors on the surface of Gram negative bacteria.36 Researchers have 
conjugated vancomycin to iron oxide and gold-based nanoparticles, which showed increased 
accumulation near the site of infection.45 Another example of nanoparticle based drug targeting 
used silica nanoparticles conjugated to vancomycin.46 Lectins can also be used as a ligand to 
actively target bacteria. In a study involving Helicobacter pylori, mannose or fucose-specific 
lectins were able to successfully target carbohydrate-based receptors on the bacterial cell 
surface.47 
 
Figure 7. Bacteria-induced Enhanced Permeability Effect for accumulation of nanoparticles at the site of 
infection. The inflammatory process creates a localized area of increased fluid accumulation, which 
nanoparticles exploit for therapeutic effect.40 
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Figure 8. In vivo evidence for the enhanced permeability and retention effect. Rats were given an S. 
aureus infection in their calves, and an injection of liposomes. The shaded regions in the calf show 
increased accumulation of the liposomes over time. The scintigraphy was done using 99mTc.41 
 
 
The selective attraction between antigens and antibodies offers another option for drug 
targeting, such as antibodies against endotoxins to target Gram-negative bacteria or antibodies 
against lipoteichoic acid to target Gram-positive bacteria.36 Black et al developed inorganic 
nanoparticles functionalized with anti-bacterial antibodies, and observed effective targeting to 
bacteria.48 Conjugating inorganic nanoparticles with antibodies greatly increased their targeting 
and efficacy. Dai et al used nanoparticles modified with Salmonella antibodies and were able to 
achieve targeting and low toxicity to the host.49  
 
There are several other molecules which can allow active targeting to bacteria, such as phage 
tail-spikes and aptamers. Studies using these molecules have shown strong attraction to 
Salmonella typhimurium and Mycobacterium tuberculosis.50,51 They may emerge as effective 
ligands for nanoparticles in the near future. 
 
An interesting development in targeted drug delivery uses a technique called molecular 
imprinting in which cavities are developed into the nanoparticles.36 The cavities act as receptors 
for features on the bacterial surface like lipopolysaccharides. This is achieved through a process 
called inverse microemulsion polymerization, and has been used to target lipopolysaccharides 
on Pseudomonas aeruginosa.52 Researchers have attempted to target beta-lactamase using the 
molecular-imprinting technique as well.36 
  
5.3 Microenvironment Responsiveness 
  
The microenvironment offers a variety of unique characteristics that drug delivery systems can 
respond to. Chen et al highlights several of those features, such as enzymes secreted by 
bacteria and pH. Bacteria secrete enzymes such as lipases that are concentrated around 
infection. Researchers used this idea to develop polyphosphodiester nanoparticles, sometimes 
called nanogels, that are degraded by lipases. Lipases are also utilized by polymeric 
nanoparticles linked to fatty acid esters or anhydrides.36 Other bacterial enzymes, like 
hyaluronidase, are being used in a similar way.53 Ji et al showed that hyaluronidase degrades 
nanoparticles into reactive oxygen species that are effective in dispersing biofilms. 
  
A common feature of bacterial infections, especially those associated with a biofilm, is 
anaerobic glycolysis. The pH of the microenvironment is lowered by anaerobic glycolysis 
performed by bacteria. Some nanoparticles have been developed to respond to changing pH. 
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For example, researchers developed mesoporous silica nanoparticles loaded with b-lactam and 
further surrounded by a pH responsive metallic shell. At the site of infection, the shell degrades 
due to the lowered pH, and leaves the highly porous nanoparticle, which rapidly releases its 
antibiotic load.54 pH stimuli have been used to control drug release in the gastrointestinal tract, 
to intracellular lysosomes, or to the microenvironment surrounding bacteria. In one example, 
bismaleimide was used as a link to block pores in the nanoparticle from opening, but will move 
when protonated by a more acidic environment. The altered form of bismaleimide allowed pores 
to open and the antibiotic to be released.31 In another example, polymeric nanoparticles made 
of poly(L-histidine), polylactide-polyglycolide, and polyethyl glycol, switch from a negative 
charge to a positive charge when subjected to more acidic conditions. The switch promoted 
electrostatic binding to bacteria and delivery of antibiotics to the site of infection.55 Figure 9 
summarizes this process. 
 
 
 
Figure 9. An example of environmental responsiveness to promote accumulation of nanoparticles at the 
site of infection. Functionalized polymeric nanoparticles promote selective attraction to bacteria by 
exploiting electrostatic potential. The switch is promoted by the low pH that accompanies bacterial 
infection.55 
 
5.4 Liposomes 
 
The interaction that occurs between nanoparticles and bacteria during drug delivery is 
dependent on the chemistry of the nanoparticle. The fusion mechanism between liposomes and 
bacteria is controlled by the electrostatic and hydrophobic forces that attract liposomes to the 
bacterial membrane. Passive fusion of liposomes occurs through the “stalk mechanism.” The 
liposome forms an hour-glass shaped stalk that promotes fusion and reorganization with the 
bacterial membrane. This mechanism is influenced by the composition of the liposome.34 
	 16	
 
Controlled fusion of liposomes is accomplished using a trigger. Like other nanoparticles, 
liposomes use chemical interactions or a ligand as their trigger. For example, conjugating 
polyethylene glycol to the liposome increases its hydrophilicity and inhibits spontaneous fusion 
with cell membranes of host cells.34 Kirputin et al developed pH-sensitive liposomes. The 
liposome contained disulfide linkages connecting polyethylene glycol to a lipid called 
dioleylphosphatidylethanolamine. The disulfide linkages were pH sensitive, lysing around pH 
5.5. The result was detachment of polyethylene glycol. The remaining liposome was then able 
to fuse to bacterial cells or phagocytes using the stalk mechanism.56 In another study, 
researchers developed a ligand that mimicked an antigen present on gastric epithelial cells. The 
ligand was recognized by a receptor expressed by Helicobacter pylori. The tight interaction 
between the ligand and bacterial receptor promoted liposomal fusion with the bacterium and 
subsequent release of antibiotic.57 
  
5.5 Nanoparticles as Antibiotics 
 
Nanoparticles, especially metal-based nanoparticles, are intrinsically antibacterial. There are 
several mechanisms through which nanoparticles can achieve this action. According to Wang et 
al the leading causes of direct antibacterial action from nanoparticles are oxidative stress, 
metal-ion release, or other non-oxidative mechanisms.58 These mechanisms are highlighted in 
Figure 10. 
  
 
 
 
Figure 10. The toxicity of metallic nanoparticles against bacteria through three mechanisms: oxidative 
stress, metal ion release, and non-oxidative stress.31  
 
 
Oxidative stress is the most important of these three mechanisms. Various inorganic 
nanoparticles are reducing agents and convert the oxygen species of the microenvironment into 
reactive oxygen species. Reactive oxygen species increase bacterial membrane permeability 
and eventually erode membrane integrity. Additionally, intracellular reactive oxygen species 
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promote expression of oxidative proteins that result in death of the bacteria.58 Nanoparticles 
produce several types of reactive oxygen species. Magnesium and calcium based nanoparticles 
are associated with superoxide radicals (O-2), while zinc-oxide based nanoparticles produce 
hydrogen peroxide (H2O2) and hydroxyl radicals (·OH).59 Metal-based nanoparticles also attack 
bacteria by releasing metal ions that disrupt protein function in the cell, but this is thought to be 
a minor contributor to antimicrobial action. 
  
An important non-oxidative mechanism is covalent bonding to the cell wall. This mechanism 
alters cell metabolism by restraining vital proteins, for example the proteins involved in the 
electron transport chain. However, this antibacterial activity is not very effective against gram 
negative bacteria.31 
 
5.6 Overcoming Resistance Mechanisms 
   
As previously mentioned, efflux pumps are an effective way for bacteria to survive antibiotic 
treatment. Current research is developing ways to overcome this mechanism of resistance 
using chemicals like piperine. Piperine is an alkaloid chemical sometimes found in traditional 
medicines. In one study, a strain of methicillin-resistant S. aureus that utilized efflux pumps were 
subjected to nanoparticles loaded with gentamycin. Two kinds of nanoparticles were given as 
treatment: bare liposomes or liposomes containing piperine. The bacteria were also given 
ethidium bromide, which fluoresces when bound to nucleic acids inside bacteria. Data from the 
experiment showed increased fluorescent activity and increased bactericidal activity in the 
piperine loaded liposomes versus the bare liposomes, allowing the researchers to conclude that 
piperine blocked the efflux pumps.60 These nanoparticles reduced efflux pump mediated 
antibiotic resistance in S. aureus. 
  
Nanoparticles offer a protective barrier between degradative enzymes and the antibiotic thereby 
preventing inactivation of the drug. Alipour et al used liposomes to encapsulate tobramycin and 
polymyxin B. These polycationic compounds are prone to inactivation by polyanionic endotoxins 
like lipopolysaccharides and lipoteichoic acid or by other extracellular components like mucin. 
During their in vitro study, free antibiotic and liposome-containing antibiotic were incubated in 
several different cultures of polyanionic compounds. After incubation, the potency of each drug 
was tested. Both the free and packaged antibiotic showed reduced efficacy by the polyanionic 
environment as a function of concentration. However, the concentration of polyanionic 
compounds needed to inactivate free antibiotic was much less than that needed for antibiotic 
loaded into a liposome.61 The researchers further confirmed their data by applying the antibiotic 
to P. aeruginosa from the sputa of a cystic fibrosis patients. The sputa provide a polyanionic 
environment that could inactivate the antibiotic. They found the packaged antibiotic to have four-
fold higher activity than the free antibiotic, and was particularly helpful for polymyxin B efficacy.61 
  
5.7 Nanoparticle Applications to Biofilms  
 
Nitric oxide has shown to inhibit biofilm formation and break up previously formed biofilms. The 
review by Diab et al highlighted a couple ways nitric oxide is being delivered to biofilms for this 
purpose.34 In Jadeleza et al, liposomes were loaded with isosorbide mononitrate, and used to 
release nitric oxide in a slow, controlled manner in a biofilm. The drug release ablated a biofilm 
of S. aureus.62,34 In another study, nitric oxide was released by polymer nanoparticles and 
prevented planktonic bacteria from attaching to a biofilm of P. aeruginosa through stimulating 
phosphodiesterase activity. This action effectively inhibited biofilm growth.63  
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Another approach is using nanoparticles to penetrate the biofilm. Several studies have been 
done to compare the penetration of antibiotics loaded into nanoparticles and soluble antibiotic. 
In Alipour et al the researchers used polymyxin B loaded into liposomes.61 Using microscopy 
methods, the researchers measured drug penetration into P. aeruginosa biofilms over a period 
of 16 hours. Polymyxin B showed improved penetration compared to soluble drug. A similar 
experiment was conducted using amikacin against in vivo respiratory infections of 
Pseudomonas. Although the free amikacin was unable to affect the biofilms, amikacin loaded 
into liposomes were able to penetrate and destroy biofilms. The researchers accounted this 
improved action to better drug penetration and sustained drug release by the liposomes.64  
 
5.8 Targeting Nanoparticles to Phagocytes 
 
Nanoparticles offer a solution to persistent intracellular bacteria by targeting antibiotics to 
phagocytic cells. As Zaidi et al note, nanoparticles target phagocytes by promoting 
phagocytosis.31 Once inside the phagocytic cells, the nanoparticles release their antibiotic 
payload. A recently published study from Iowa State used polyanhydride nanoparticles to target 
Brucella melitensis in murine macrophages.32 When comparing soluble rifampicin against the 
nanoparticle loaded rifampicin, the nanoparticle outperformed. By 72-hours post infection, the 
macrophages given nanoparticle treatment had zero colony-forming-units of Brucella. 
Meanwhile, the soluble treated bacteria still managed over 10000 colony-forming-units by 72-
hours post infection, and were growing in population. This data suggests that treatment using 
soluble antibiotic selected for resistant strains, while nanoparticle treatment was able to fully 
remove the infection. In this way, the authors concluded that nanoparticles could provide 
increased efficacy and dose sparing for intracellular antibiotic treatment.32 Their data is 
summarized in Figure 11. 
 
 
Figure 11. Data from the Lueth et al in vitro study. “Soluble” represents free rifampicin. 20:80 CPH:SA 
and 20:80 CPTEG:CPH are two different polyanhydride nanoparticle compositions.32 
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Passive and active targeting to phagocytes occurs by using opposite features as those for 
targeting to infection. For example, rather than the positive charge that promotes attraction of a 
nanoparticle to bacteria, a net negative charge of the surface of the nanoparticle promotes 
internalization by phagocytic cells.32,25 Also, rather than using hydrophilicity to promote 
distribution of the nanoparticle in the body, increasing hydrophobicity promotes internalization 
by phagocytes.26 Certain ligands attached to the surface of nanoparticles increase 
internalization of the nanoparticles by phagocytic cells.36 Nanoparticles featuring mannose, 
amylopectin, or animal derived albumin can enhance nanoparticle uptake by phagocytic cells.31 
Antibodies could also potentiate internalization by phagocytic cells.25 Promoting nanoparticle 
internalization would improve antibiotic efficacy against intracellular organisms. 
 
6. CONCLUSION 
 
The emergence of antibiotic-resistant strains of bacteria is outpacing the development of new 
antibiotics, with new antibiotics quickly encountering resistance within a few short years of 
development. This issue is having a significant impact on health care, and will only become 
worse with the emergence of stronger multiple drug resistant strains of pathogenic bacteria. Our 
best chance to counter this growing concern is through breakthrough innovations, such as 
nanotechnology. The application of nanotechnologies is becoming a driving force behind 
ongoing changes in the antimicrobial field.  Nanoparticles show promise as a drug delivery 
approach to defeat bacterial defenses through passive and active targeting, anti-biofilm action, 
microenvironment responsiveness, and inherent antimicrobial action. Perhaps continued 
improvement to the nanoparticle approach may bypass the issue of antibiotic resistance 
altogether. 
 
In addition to these advantages, new innovations in nanoparticle technology like stimulus-
response and other novel modes of killing mechanisms are being developed. Simultaneous 
real-time detection and therapy, known as theranostic nanoparticle technology, may 
demonstrate effective antibiotic treatment. Additionally, nanoparticles can be applied ways 
beyond drug delivery. As highlighted in Figure 12 (page 20), nanoparticles have many 
applications in preventative medicine by coating prosthetics or other medical implants and 
devices that often result in nosocomial infections. 
 
Nanoparticles’ rapid emergence as an antibiotic delivery method has elicited some 
concerns.  There must be thorough examination of their long-term safety, and assessments of 
the biocompatibility between nanoparticles and the human body prior to large clinical studies. 
Further study of the retention and clearance, pharmacokinetics, biodistribution, and immune 
surveillance on the many varieties of nanoparticles is a challenge that will require the 
development of efficient in-vitro and in-vivo screening technologies. Despite the concerns, 
continuing research into production methods, composition, and payloads means nanoparticle 
technology will play a more significant and expanding role in our fight against bacterial infection. 
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Figure 12. The potential applications of nanoparticles.58 
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